Precision-drug maker Impact Therapeutics ignites IPO frenzy
The biotech scored a strong debut on the Hong Kong stock market after launching a targeted “synthetic lethality” drug that can kill off mutated cancer cells Key Takeaways: The company’s…
Recent Articles
RELATED ARTICLES
-
Jacobio Pharma poised to turn a profit from precision cancer drugs
- Hong Kong to welcome world-leading siRNA company as Ribo launches its IPO
- Rethinking bigger Is better: China’s long march toward higher-capacity energy storage cells
- PV cell maker Yingfa Ruineng chases IPO, charged up by National Green Fund backing
- Eye drug maker VivaVision feels the strain in IPO funding dash
